… Erlotinib (Tarceva) is a reversible and highly specific inhibitor of epidermal growth factor …
with EGFR-positive non-small cell lung cancer after failure of platinum-containing chemotherapy …

… given as thirdline therapy may provide the clearest picture for the role of erlotinib in the
treatment of NSCLC. Docetaxel, a cytotoxic agent that produced a 7% response rate, provided a …

… This phase II study of erlotinib in patients with HER1/EGFR-expressing non–small-cell lung
cancer previously treated with platinum-based chemotherapy evaluated tumor response, …

… The TKIs erlotinib and gefitinib went on to gain conditional approval as … only erlotinib secured
continued approval for use in the United States. In this paper, we review the role of erlotinib …

… [35] In summary, the role of single agent erlotinib as first-line therapy in patients with EGFR
wildtype NSCLC is not very well defined. On the basis of the randomized trial, single agent …

… to erlotinib; however, those who had never smoked had a significant survival benefit from
erlotinib. To clarify the role of EGFR in the outcome of non–small-cell lung cancer, we …

… and the good toxicity profile of erlotinib make it a reasonable candidate for testing … role of
erlotinib therapy in advanced NSCLC. It summarizes current data and perspectives of erlotinib …

… This review summarizes the potential roles of erlotinib and afatinib in SCC of the lung. The
authors explore the rationale of targeting EGFR in SCC and the pharmacological properties of …

… of induction of autophagy with erlotinib treatment in NSCLC cell lines carrying activating
EGFR mutations. More importantly, our findings supported the role of autophagy in enhancing …

… The present review discusses the role of erlotinib in the treatment of NSCLC. … the most
studied targets for cancer therapy. The present review discusses the role of erlotinib, an anti-EGFR …